Andrew J. Armstrong, MD, discusses the updated results and the clinical implications of the final survival analysis of the ARCHES trial, which he coauthored.
Enzalutamide Plus ADT Boosts Survival in mHSPC
Treatment with the androgen-receptor inhibitor enzalutamide plus androgen deprivation therapy led to significant survival benefits in patients with metastatic hormone-sensitive prostate cancer.
Andrew J. Armstrong, MD, MSc, discusses updated results from the phase 3 ARCHES trial in metastatic hormone-sensitive prostate cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Priority Review to Giredestrant for ER-Positive Early Breast Cancer
2
Bispecific-Based Approaches Highlight Key Multiple Myeloma Data Set to Emerge at EHA 2026
3
Breast Cancer Experts Spotlight Practice-Informing and Thought-Provoking Data From ASCO 2026
4
CELMoDs and Bispecifics Break Through Across Lymphomas and Leukemias at EHA 2026
5